stockportfolio.pro
Wave Life Sciences Ltd. (WVE)
Healthcare · Biotechnology · NasdaqGM
Wave Life Sciences Ltd. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $3.70M | $14.41M | $15.98M | $20.08M | $40.96M | $3.65M | $113.31M | $108.30M | $42.73M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-55.66M | $-101.98M | $-146.65M | $-193.64M | $-149.91M | $-122.25M | $-161.82M | $-57.51M | $-97.01M | $-204.38M |
| Net margin | -3748.1% | -2753.2% | -1017.4% | -1211.5% | -746.7% | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
Source: Wave Life Sciences Ltd. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Wave Life Sciences Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track WVE in your portfolio →
Wave Life Sciences Ltd. financial history by metric
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wave Life Sciences Ltd. — frequently asked questions
What is Wave Life Sciences Ltd.'s revenue?
Wave Life Sciences Ltd. (WVE) reported revenue of $42.73M for fiscal year 2025, down 60.5% from the prior year, according to its SEC filings.
Is Wave Life Sciences Ltd. profitable?
No — WVE reported a net loss of $-204.38M in fiscal 2025.
What is WVE's P/E ratio?
Wave Life Sciences Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Wave Life Sciences Ltd. growing?
WVE's revenue grew at roughly 16.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Wave Life Sciences Ltd. have?
As of fiscal year 2025, WVE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Wave Life Sciences Ltd.'s market cap?
Wave Life Sciences Ltd. (WVE) has a market capitalization of about $1.11B, based on the latest data in our nightly-refreshed cache.
When does Wave Life Sciences Ltd.'s fiscal year end?
WVE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Wave Life Sciences Ltd.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.